专利检索 ap:("Nurix Therapeutics, Inc." OR "Gilead Sciences, Inc.") AND inv:"John Buell" 第 1 页

1.

发明公开
BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF 审中-公开

公开(公告)号：US20240025923A1

公开(公告)日：2024-01-25

申请号：US18346745

申请日：2023-07-03

申请人： Nurix Therapeutics, Inc. , Gilead Sciences, Inc.

发明人： Hunter P. Shunatona , Galen Paul Shearn-Nance , Scott A. Mitchell , John Buell

IPC分类号： C07D519/00

CPC分类号： C07D519/00

摘要： The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteosome pathway, and method for treating diseases modulated by HPK1.

2.

发明授权
Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof 有权

公开(公告)号：US11739101B2

公开(公告)日：2023-08-29

申请号：US17308879

申请日：2021-05-05

申请人： Nurix Therapeutics, Inc. , Gilead Sciences, Inc.

发明人： Hunter P. Shunatona , Galen Paul Shearn-Nance , Scott A. Mitchell , John Buell

IPC分类号： C07D519/00 , C07D471/04 , C07D487/14 , C07D471/10 , A61P31/12 , A61P35/00 , A61P37/02 , A61P31/18 , A61P31/20 , A61K31/4545 , A61K47/55

CPC分类号： C07D519/00

摘要： The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteosome pathway, and method for treating diseases modulated by HPK1.

3.

发明申请
BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF 有权

公开(公告)号：US20210355140A1

公开(公告)日：2021-11-18

申请号：US17308879

申请日：2021-05-05

申请人： Nurix Therapeutics, Inc. , Gilead Sciences, Inc.

发明人： Hunter P. Shunatona , Galen Paul Shearn-Nance , Scott A. Mitchell , John Buell

IPC分类号： C07D519/00

摘要： The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteosome pathway, and method for treating diseases modulated by HPK1.

4.

发明公开
BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF 审中-公开

公开(公告)号：US20240018162A1

公开(公告)日：2024-01-18

申请号：US18054118

申请日：2022-11-09

申请人： Nurix Therapeutics, Inc. , Gilead Sciences, Inc.

发明人： John Buell , Frederick Cohen , Ryan Pemberton , Hunter P. Shunatona , Lan Wang , Mark Edward Zak

IPC分类号： C07D519/00

CPC分类号： C07D519/00

摘要： The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by HPK1.

5.

发明授权
Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof 有权

公开(公告)号：US12091426B2

公开(公告)日：2024-09-17

申请号：US18054118

申请日：2022-11-09

申请人： Nurix Therapeutics, Inc. , Gilead Sciences, Inc.

发明人： John Buell , Frederick Cohen , Ryan Pemberton , Hunter P. Shunatona , Lan Wang , Mark Edward Zak

IPC分类号： C07D519/00

CPC分类号： C07D519/00

摘要： The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by HPK1.